DiaSorin Inc.
6 recall(s) on record — most severe on record: Class II.
Recalls by year
- Recalls (6)
Registered facilities (5)
- DiaSorin Deutschland GmbH FEI 3004434309 · DE
- DIASORIN INC. FEI 2182595 · MN
- DiaSorin Italia S.p.A UK Branch FEI 3008576040 · GB
- DiaSorin Italia S.p.A. FEI 3002808212 · IT
- DiaSorin Canada Inc. FEI 3012449645 · CA
Recalls & enforcement
- Class IIOngoing2024-11-07Customer complaints were received alleging leaking devices and insufficient buffer volume. Diasorin's internal investigation determined that 0.14% of the LIAISON Q.S.E.T. Device Plus in the lots identified have loose clear caps, which may allow buffer to leak from the tube. A sto…
- Class IIOngoing2023-12-13DiaSorin has identified that lots 136344, 136344A, 136344B, 136344C, 136520, 136520A, 136520B, 136520C, 136604, 136703, 136703A, 136703B, 136703C 136775of LIAISON HSV-2 Type Specific IgG assay may produce increased equivocal and/or false positive results.
- Class IITerminated2020-11-23Potential for system to produce falsely elevated parathyroid hormone (PTH) results from patient samples.
- Class IIOngoing2020-07-17Printed label inside the box lid of the Parvovirus has the incorrect Lot Specific Constant value
- Class IITerminated2016-07-13DiaSorin is issuing an urgent medical device correction for the LIAISON® Estradiol II Gen assay. Due to the risk of a recently identified cross reactivity, the LIAISON® Estradiol II Gena assay should not be used to test patients being treated with fulvestrant (Faslodex).
- Class IITerminated2015-03-16Instability in the PRO-Trac II Tacrolimus ELISA kit which may cause falsely elevated patient results.
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. We restate the public record only — measured facts, never risk verdicts.
Cite this record
RegWarden. “DiaSorin Inc. — FDA compliance profile.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/company/oo-9051149-diasorin-inc/
Alerts for DiaSorin Inc.
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.